Quality of Thoracic Lymph Node Evaluation in the Department of Defense According to the American College of Surgeons Commission on Cancer Surveillance Measure: Is There a Survival Benefit?

To improve the quality of cancer operations, the American College of Surgeons published Operative Standards for Cancer Surgery, which has been incorporated into Commission on Cancer (CoC) accreditation requirements. We sought to determine if compliance with operative standards was associated with technical surgical outcomes. Oncologic operative reports from 2017 at a CoC and non-CoC institution were examined for documentation of Operative Standards essential steps. Lymph node (LN) yield for lung and colon cases and re-excision rates for breast cases were recorded. Correct documentation was poor for colon, breast, and lung cases with numerous elements documented in <10% of operative reports at both centers. For lung cases, there was no significant difference in meeting ≥10 LN benchmark or average LN yield between the 2 institutions. For colon cases, average lymph node yield was lower in the non-CoC facility, but there was no significant difference in meeting ≥12 LN benchmark. For breast cases, re-excision rates were similar in both programs. Many essential steps in Operative Standards were poorly documented in operative reports, regardless of CoC status. Achieving benchmark technical surgical outcomes was not associated with documented compliance with these standards. Whether improved documentation leads to better surgical outcomes requires further investigation.

Download Full-text

Quality of Care along the Cancer Continuum: Does Receiving Adequate Lymph Node Evaluation for Colon Cancer Lead to Comprehensive Postsurgical Care?

Journal of the American College of Surgeons ◽

10.1016/j.jamcollsurg.2012.05.014 ◽

2012 ◽

Vol 215 (3) ◽

pp. 400-411 ◽

Cited By ~ 11

Author(s):

Helen M. Parsons ◽

Todd M. Tuttle ◽

Karen M. Kuntz ◽

James W. Begun ◽

Patricia M. McGovern ◽

...

Keyword(s):

Colon Cancer ◽

Quality Of Care ◽

Lymph Node ◽

Lymph Node Evaluation ◽

Adequate Lymph Node

Download Full-text

Lymph Node Evaluation of Colon Cancer and Its Association with Improved Staging and Survival in the Department of Defense Health Care System

Annals of Surgical Oncology ◽

10.1245/s10434-009-0620-4 ◽

2009 ◽

Vol 16 (11) ◽

pp. 3080-3086 ◽

Cited By ~ 12

Author(s):

Sukhyung Lee ◽

Luke J. Hofmann ◽

Kurt G. Davis ◽

Brad E. Waddell

Keyword(s):

Health Care ◽

Colon Cancer ◽

Lymph Node ◽

Health Care System ◽

Department Of Defense ◽

Lymph Node Evaluation ◽

Care System

Download Full-text

Survival benefit of para-aortic lymph node evaluation in endometrioid endometrial carcinoma

10.3802/jgo.2021.32.s1.e15 ◽

2021 ◽

Author(s):

Khemanat Khemworapong ◽

Pattra Wisarnsirirak ◽

Atthapon Jaishuen ◽

Boonlert Viriyapak ◽

Pisutt Srichaikul ◽

...

Keyword(s):

Lymph Node ◽

Endometrial Carcinoma ◽

Survival Benefit ◽

Aortic Lymph Node ◽

Endometrioid Endometrial Carcinoma ◽

Lymph Node Evaluation

Download Full-text

Quality of care for cervical and endometrial cancer patients: the impact of different techniques of sentinel lymph node mapping on patient satisfaction.

10.26226/morressier.5770e29dd462b80290b4c458 ◽

2016 ◽

Author(s):

Alessandro Buda

Keyword(s):

Endometrial Cancer ◽

Patient Satisfaction ◽

Quality Of Care ◽

Lymph Node ◽

Sentinel Lymph Node ◽

Cancer Patients ◽

Sentinel Lymph Node Mapping ◽

Lymph Node Mapping ◽

The Impact

Download Full-text

Faculty Opinions recommendation of No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal of the Multicenter Selective Lymphadenectomy Trial-I final report.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725392317.793505886 ◽

2015 ◽

Author(s):

Iris Zalaudek ◽

Aimilios Lallas

Keyword(s):

Lymph Node ◽

Sentinel Lymph Node ◽

Sentinel Lymph Node Biopsy ◽

Survival Benefit ◽

Critical Appraisal ◽

Lymph Node Biopsy ◽

Final Report ◽

Node Biopsy ◽

Selective Lymphadenectomy

Download Full-text

Improving the quality of life of patients with breast cancer-related lymphoedema by lymphaticovenous anastomosis (LVA): study protocol of a multicentre randomised controlled trial

BMJ Open ◽

10.1136/bmjopen-2019-035337 ◽

2020 ◽

Vol 10 (1) ◽

pp. e035337 ◽

Cited By ~ 1

Author(s):

Joost Wolfs ◽

Jop Beugels ◽

Merel Kimman ◽

Andrzej A Piatkowski de Grzymala ◽

Esther Heuts ◽

...

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Lymph Node ◽

Randomised Controlled Trial ◽

Conservative Treatment ◽

Cancer Treatment ◽

Controlled Trial ◽

Breast Cancer Treatment ◽

Randomised Controlled

IntroductionEarly breast cancer detection and advancements in treatment options have resulted in an increase of breast cancer survivors. An increasing number of women are living with the long-term effects of breast cancer treatment, making the quality of survivorship an increasingly important goal. Breast cancer-related lymphoedema (BCRL) is one of the most underestimated complications of breast cancer treatment with a reported incidence of 20%. A microsurgical technique called lymphaticovenous anastomosis (LVA) might be a promising treatment modality for patients with BCRL. The main objective is to assess whether LVA is more effective than the current standard therapy (conservative treatment) in terms of improvement in quality of life and weather it is cost-effective.Methods and analysisA multicentre, randomised controlled trial, carried out in two academic and two community hospitals in the Netherlands. The study population includes 120 women over the age of 18 who have undergone treatment for breast cancer including axillary treatment (sentinel lymph node biopsy or axillary lymph node dissection) and/or axillary radiotherapy, presenting with an early stage lymphoedema of the arm, viable lymphatic vessels and received at least 3 months conservative treatment. Sixty participants will undergo the LVA operation and the other sixty will continue their regular conservative treatment, both with a follow-up of 24 months. The primary outcome is the health-related quality of life. Secondary outcomes are societal costs, quality adjusted life years, cost-effectiveness ratio, discontinuation rate of conservative treatment and excess limb volume.Ethics and disseminationThe study was approved by the Ethics Committee of Maastricht University Medical Center (METC) on 19 December 2018 (NL67059.068.18). The results of this study will be disseminated in presentations at academic conferences, publications in peer-reviewed journals and other news media.Trial registration numberNCT02790021; Pre-results.

Download Full-text

Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?

Current Oncology ◽

10.3390/curroncol28010027 ◽

2020 ◽

Vol 28 (1) ◽

pp. 252-259

Author(s):

Warren Fingrut ◽

Wendy Davis ◽

Eric McGinnis ◽

Karen Dallas ◽

Khaled Ramadan ◽

...

Keyword(s):

Quality Of Life ◽

Monoclonal Antibody ◽

Flow Cytometry ◽

Acute Lymphoblastic Leukemia ◽

Survival Benefit ◽

Lymphoblastic Leukemia ◽

Surface Expression ◽

Inotuzumab Ozogamicin ◽

Cell Acute Lymphoblastic Leukemia

Salvage options for patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) include inotuzumab ozogamicin (InO), a recombinant, humanized anti-CD22 monoclonal antibody conjugated to the cytotoxic antibiotic calicheamicin. However, the benefit of InO in patients with dim CD22 expression remains unclear. We present a case of a patient with B-ALL who responded to InO despite only dim surface expression of CD22 by flow cytometry, achieving a survival benefit concordant with that reported in the literature and maintaining a good quality of life as a transfusion-independent outpatient. Our observation has broad relevance to clinicians who manage patients with B-ALL who are candidates for InO.

Download Full-text